###begin article-title 0
Synthetic RGDS peptide attenuates lipopolysaccharide-induced pulmonary inflammation by inhibiting integrin signaled MAP kinase pathways
###end article-title 0
###begin p 1
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
###end p 1
###begin title 2
Background
###end title 2
###begin p 3
###xml 235 239 235 239 <italic xmlns:xlink="http://www.w3.org/1999/xlink">i.t.</italic>
Synthetic peptides containing the RGD sequence inhibit integrin-related functions in different cell systems. Here, we investigated the effects of synthetic Arg-Gly-Asp-Ser (RGDS) peptide on key inflammatory responses to intratracheal (i.t.) lipopolysaccharide (LPS) treatment and on the integrin signaled mitogen-activated protein (MAP) kinase pathway during the development of acute lung injury.
###end p 3
###begin title 4
Methods
###end title 4
###begin p 5
###xml 43 48 43 48 <italic xmlns:xlink="http://www.w3.org/1999/xlink">i.t. </italic>
###xml 124 126 120 122 <sub xmlns:xlink="http://www.w3.org/1999/xlink">v </sub>
###xml 138 140 131 133 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3 </sub>
###xml 161 165 <span type="species:ncbi:10090">Mice</span>
Saline or LPS (1.5 mg/kg) was administered i.t. with or without a single dose of RGDS (1, 2.5, or 5 mg/kg, i.p.), anti-alphav or anti-beta3 mAb (5 mg/kg, i.p.). Mice were sacrificed 4 or 24 h post-LPS.
###end p 5
###begin title 6
Results
###end title 6
###begin p 7
###xml 614 616 606 608 <sub xmlns:xlink="http://www.w3.org/1999/xlink">v </sub>
###xml 802 804 791 793 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3 </sub>
A pretreatment with RGDS inhibited LPS-induced increases in neutrophil and macrophage numbers, total protein levels and TNF-alpha and MIP-2 levels, and matrix metalloproteinase-9 activity in bronchoalveolar lavage (BAL) fluid at 4 or 24 h post-LPS treatment. RGDS inhibited LPS-induced phosphorylation of focal adhesion kinase and MAP kinases, including ERK, JNK, and p38 MAP kinase, in lung tissue. Importantly, the inhibition of the inflammatory responses and the kinase pathways were still evident when this peptide was administered 2 h after LPS treatment. Similarly, a blocking antibody against integrin alphav significantly inhibited LPS-induced inflammatory cell migration into the lung, protein accumulation and proinflammatory mediator production in BAL fluid, at 4 or 24 h post-LPS. Anti-beta3 also inhibited all LPS-induced inflammatory responses, except the accumulation of BAL protein at 24 h post-LPS.
###end p 7
###begin title 8
Conclusion
###end title 8
###begin p 9
###xml 63 64 59 60 <sub xmlns:xlink="http://www.w3.org/1999/xlink">v</sub>
These results suggest that RGDS with high specificity for alphavintegrins attenuates inflammatory cascade during LPS-induced development of acute lung injury.
###end p 9
###begin title 10
Background
###end title 10
###begin p 11
###xml 191 192 191 192 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B1">1</xref>
###xml 575 577 572 574 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2 </sub>
###xml 599 600 592 593 <sub xmlns:xlink="http://www.w3.org/1999/xlink">4</sub>
###xml 604 606 594 596 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1 </sub>
###xml 615 616 601 602 <sub xmlns:xlink="http://www.w3.org/1999/xlink">5</sub>
###xml 620 622 603 605 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1 </sub>
###xml 655 656 635 636 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 721 722 701 702 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B2">2</xref>
###xml 746 748 723 725 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2 </sub>
###xml 766 768 739 741 <sub xmlns:xlink="http://www.w3.org/1999/xlink">4 </sub>
###xml 778 780 747 749 <sub xmlns:xlink="http://www.w3.org/1999/xlink">5 </sub>
###xml 876 877 845 846 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B2">2</xref>
Acute lung injury is characterized by an intense pulmonary inflammatory response, with neutrophil recruitment, interstitial edema, disruption of epithelial integrity, and parenchymal injury [1]. The migration of leukocytes to inflamed sites depends on the interactions of various integrins expressed on leukocytes with the Ig superfamily of cell adhesion molecules (ICAM-1 and ICAM-2) present on the endothelium and with the extracellular matrix ligands. Multiple integrins participate in neutrophil migration into the lung during LPS-induced lung injury. In addition to beta2 integrin (CD18), alpha4beta1 and alpha5beta1 integrins also contribute to beta2-independent neutrophil migration during pulmonary inflammation [2]. However, neither beta2 blockade nor alpha4 plus alpha5 blockade reduced neutrophil accumulation in the parenchyma and only minimally in the airspaces [2]. These findings suggest that there are functionally redundant alternative integrin pathways that signal neutrophil recruitment to the lung and inflammatory responses.
###end p 11
###begin p 12
###xml 50 51 46 47 <sub xmlns:xlink="http://www.w3.org/1999/xlink">5</sub>
###xml 55 56 48 49 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 69 70 55 56 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 77 78 59 60 <sub xmlns:xlink="http://www.w3.org/1999/xlink">v</sub>
###xml 82 83 61 62 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 90 91 65 66 <sub xmlns:xlink="http://www.w3.org/1999/xlink">v</sub>
###xml 95 96 67 68 <sub xmlns:xlink="http://www.w3.org/1999/xlink">6</sub>
###xml 103 104 71 72 <sub xmlns:xlink="http://www.w3.org/1999/xlink">8</sub>
###xml 108 109 73 74 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 116 117 77 78 <sub xmlns:xlink="http://www.w3.org/1999/xlink">v</sub>
###xml 121 122 79 80 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 129 130 83 84 <sub xmlns:xlink="http://www.w3.org/1999/xlink">v</sub>
###xml 134 135 85 86 <sub xmlns:xlink="http://www.w3.org/1999/xlink">5</sub>
###xml 146 147 93 94 <sub xmlns:xlink="http://www.w3.org/1999/xlink">v</sub>
###xml 151 152 95 96 <sub xmlns:xlink="http://www.w3.org/1999/xlink">8</sub>
###xml 214 215 158 159 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B3">3</xref>
###xml 307 308 251 252 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B4">4</xref>
###xml 449 450 393 394 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B5">5</xref>
Many members of the integrin family, such as alpha5beta1, alphaIIbeta3, alphavbeta3, alphavbeta6, alpha8beta1, alphavbeta1, alphavbeta5, and alphavbeta8, recognize the Arg-Gly-Asp (RGD) motif within their ligands [3], which include fibronectin, fibrinogen, vitronectin, von Willebrand factor and collagens [4]. Synthetic peptides containing the RGD sequence have been shown to compete with adhesive proteins for binding to these integrin receptors [5], and thus, inhibit integrin-related functions in different cell systems. This suggests the possibility that therapeutic RGD-containing integrin ligands could be developed to ameliorate inflammatory cascades, specifically those that cause the migration and activation of leukocytes.
###end p 12
###begin p 13
###xml 232 233 232 233 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B6">6</xref>
###xml 251 252 251 252 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B7">7</xref>
###xml 513 514 513 514 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B8">8</xref>
###xml 365 369 <span type="species:ncbi:10116">rats</span>
###xml 463 466 <span type="species:ncbi:10116">rat</span>
Several previous reports suggest the possibility that RGDS alters systemic inflammation. RGDS (i.p.) effectively inhibits collagen-triggered activation of leukocytes and platelets, such as aggregation and oxygen radical production [6]. Koning et al. [7] demonstrated binding of RGD peptide to proliferating vascular endothelial cells in LPS-induced inflammation in rats. Moreover, RGD peptide inhibits the expression of inflammatory cytokines, iNOS, and MMP-9 in rat liver after cold ischemia/reperfusion injury [8]. However, the local effect of RGDS on pulmonary inflammation has not been evaluated.
###end p 13
###begin p 14
###xml 233 234 229 230 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B9">9</xref>
###xml 459 464 455 460 <italic xmlns:xlink="http://www.w3.org/1999/xlink">i.t. </italic>
The inhibitory effect of RGD peptide on LPS-induced mitogen-activated protein (MAP) kinase activity and TNF-alpha production was shown in RAW 264.7 cell model, suggesting that LPS-induced integrin signaling converges on MAP kinases [9]. Here, we evaluated the effects of RGDS peptide on the pulmonary inflammatory responses, including leukocyte migration into the lungs, damage to the lung blood-gas barrier, and proinflammatory mediator production following i.t. LPS treatment. Furthermore, we also examined the effects of RGDS on the integrin signaled MAP kinase pathway during the development of acute lung injury.
###end p 14
###begin title 15
Materials and methods
###end title 15
###begin title 16
Reagents
###end title 16
###begin p 17
###xml 5 22 5 22 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Escherichia coli </italic>
###xml 203 204 199 200 <sub xmlns:xlink="http://www.w3.org/1999/xlink">v</sub>
###xml 217 219 213 215 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B10">10</xref>
###xml 240 242 233 235 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3 </sub>
###xml 282 284 272 274 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B11">11</xref>
###xml 5 21 <span type="species:ncbi:562">Escherichia coli</span>
###xml 292 298 <span type="species:ncbi:9986">rabbit</span>
###xml 321 327 <span type="species:ncbi:9986">rabbit</span>
###xml 354 360 <span type="species:ncbi:9986">rabbit</span>
LPS (Escherichia coli lipopolysaccharide, 055:B5), Arg-Gly-Asp-Ser (RGDS) and Arg-Gly-Glu-Ser (RGES) were purchased from Sigma (St. Louis, MO). The antibodies used in this study were: anti-integrin alphav(RMV-7) mAb [10], anti-integrin beta3 (HMbeta) mAb (BioLegend, San Diego CA) [11], anti-rabbit phospho ERK/ERK, anti-rabbit phospho JNK/JNK, and anti-rabbit phospho-p38 MAP kinase/p38 MAP kinase (New England Biolabs, Beverly, MA), and anti-phospho-focal adhesion kinase (FAK) (pY397)/anti-FAK (Santa Cruz Biotechnology, Inc., Santa Cruz, CA).
###end p 17
###begin title 18
Animal protocols
###end title 18
###begin p 19
###xml 36 40 <span type="species:ncbi:10090">mice</span>
###xml 251 255 <span type="species:ncbi:10090">Mice</span>
Specific, pathogen-free male BALB/C mice (Daehan Biolink Co. Eumsung-Gun, Chungbuk, Republic of Korea) weighing 19-21 g were used in all experiments. The Animal Care Committee of the Ewha Medical Research Institute approved the experimental protocol. Mice were cared for and handled in accordance with the National Institutes of Health (NIH) Guide for the Care and Use of Laboratory Animals.
###end p 19
###begin p 20
###xml 70 72 70 72 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B12">12</xref>
###xml 164 168 164 168 <italic xmlns:xlink="http://www.w3.org/1999/xlink">i.p.</italic>
###xml 502 504 501 503 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B13">13</xref>
###xml 505 507 504 506 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B14">14</xref>
###xml 727 728 722 723 <sub xmlns:xlink="http://www.w3.org/1999/xlink">v</sub>
###xml 732 733 724 725 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 759 760 747 748 <sub xmlns:xlink="http://www.w3.org/1999/xlink">v</sub>
###xml 774 776 759 761 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3 </sub>
###xml 929 931 914 916 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B15">15</xref>
###xml 0 5 <span type="species:ncbi:10090">Mouse</span>
###xml 308 312 <span type="species:ncbi:10090">mice</span>
Mouse pharyngeal aspiration was performed as described by Rao et al. [12]. Animals were anesthetized with a mixture of ketamine and xylazine (45 mg/kg and 8 mg/kg, i.p., respectively). Test solution (30 mul) containing LPS (1.5 mg/kg) was placed posterior in the throat and aspirated into the lungs. Control mice were administrated sterile saline (0.9% NaCl). Animals were administered with RGDS or RGES peptide (1, 2.5 or 5 mg/kg, i.p.) once one hour before LPS treatment and sacrificed 4 h post-LPS [13,14]. Animals were also administered RGDS or RGES peptide (5 mg/kg, i.p.) once at different time points (1 h before or 2 h after LPS treatment) and sacrificed 24 h post-LPS. In addition, animals were administered with alphavbeta3-blocking mAbs, anti-alphav, or anti-beta3 (5 mg/kg, i.p.) once 1 h before and sacrificed 4 h post-LPS. Animals administered with these mAbs 2 h after LPS treatment were sacrificed 24 h post-LPS [15].
###end p 20
###begin title 21
Isolation of bronchoalveolar lavage (BAL) cells, lung tissue, and cell counts
###end title 21
###begin p 22
###xml 81 83 81 83 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2+</sup>
###xml 86 88 86 88 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2+</sup>
###xml 154 155 154 155 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 157 158 157 158 <sub xmlns:xlink="http://www.w3.org/1999/xlink">4</sub>
###xml 170 171 170 171 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 174 175 174 175 <sub xmlns:xlink="http://www.w3.org/1999/xlink">4</sub>
###xml 461 463 461 463 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B16">16</xref>
###xml 549 551 549 551 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B17">17</xref>
###xml 240 245 <span type="species:ncbi:10090">mouse</span>
BAL was performed through a tracheal cannula using 0.8 ml aliquots of ice-cold Ca2+/Mg2+-free phosphate-buffered medium (145 mM NaCl, 5 mM KCl, 1.9 mM NaH2PO4, 9.35 mM Na2HPO4, and 5.5 mM dextrose; at pH 7.4) for a total of 2.4 ml for each mouse. Cell counts were determined using an electronic Coulter Counter fitted with a cell sizing analyzer (Coulter Model ZBI with a channelizer 256; Coulter Electronics, Bedfordshire, UK), as described by Lane and Mehta [16]. Neutrophils and macrophages were identified by their characteristic cell diameter [17].
###end p 22
###begin title 23
Measurement of total protein in BAL samples
###end title 23
###begin p 24
###xml 105 107 105 107 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B18">18</xref>
###xml 174 176 174 176 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B19">19</xref>
###xml 185 191 <span type="species:ncbi:9913">bovine</span>
BAL protein concentration was used as an indicator of blood-pulmonary epithelial cell barrier integrity [18]. Total protein was measured using the method devised by Hartree [19], using bovine serum albumin as a standard.
###end p 24
###begin title 25
TNF-alpha and macrophage inflammatory protein (MIP)-2 measurements
###end title 25
###begin p 26
First BAL fluid was assayed using TNF-alpha and MIP-2 enzyme-linked immunosorbent assay (ELISA) kits (R&D Systems, Minneapolis, MN) according to the manufacturer's instructions. Concentrations of TNF-alpha, and MIP-2 were determined as picograms per milliliter based on the appropriate standard curve.
###end p 26
###begin title 27
Zymographic analysis of matrix metalloproteinase-9 (MMP-9)
###end title 27
###begin p 28
###xml 150 152 150 152 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B20">20</xref>
The gelatinolytic activities of BAL fluid samples were determined by zymography using gelatin copolymerized with acrylamide, as described previously [20]. Clear zymogram bands were photographed using negative Polaroid 665 film. MMP-9 activity was quantified by densitometry using an UltroScan XL laser densitometer (LKB, Model 2222-020).
###end p 28
###begin title 29
Western blot analysis
###end title 29
###begin p 30
Lung tissue homogenate was separated on 10% SDS-polyacrylamide gels. Separated proteins were electrophoretically transferred onto nitrocellulose paper and blocked for 1 h at room temperature with Tris-buffered SAL containing 3% BSA. Membranes were then incubated with the indicated Abs and visualized by chemiluminescence (ECL).
###end p 30
###begin title 31
Fibrinogen binding assay
###end title 31
###begin p 32
###xml 146 147 144 145 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 177 179 175 177 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B13">13</xref>
Adherent cells (> 95% alveolar macrophages) were incubated in 100 mul DMEM containing 80 mug/ml fibrinogen conjugated to Alexafluor-488, 2 mM CaCl2, and 4 mg/ml BSA for 20 min [13]. Cells were then resuspended in a fixation solution. Nuclei were stained with Hoechst no. 33258 (5 mug/ml, Calbiochem) for 10 min and slides were then mounted. Images were collected using an LSM Image Examiner on a confocal laser scanning microscope (LSM-5 Pascal Exciter, Carl Zeiss, Germany).
###end p 32
###begin title 33
Lung histology
###end title 33
###begin p 34
Lungs were fixed with 10% buffered formalin at room temperature for 48 h, dehydrated, and embedded in paraffin. Sections (4 mum) were stained with hematoxylin and eosin (H&E). Light microscopic analysis of lungs was performed by blinded observation.
###end p 34
###begin title 35
Statistical analysis
###end title 35
###begin p 36
###xml 118 131 116 129 <italic xmlns:xlink="http://www.w3.org/1999/xlink">post hoc test</italic>
Values are expressed as means +/- SEM. Inter-group comparisons were performed using one-way ANOVA followed by Tukey's post hoc test. Statistical significance was set at P < 0.05.
###end p 36
###begin title 37
Results
###end title 37
###begin title 38
Effects of RGDS peptide on the recruitment of inflammatory cells to lungs
###end title 38
###begin p 39
###xml 71 76 71 76 <italic xmlns:xlink="http://www.w3.org/1999/xlink">i.t. </italic>
###xml 99 100 97 98 <sup xmlns:xlink="http://www.w3.org/1999/xlink">5</sup>
###xml 126 127 122 123 <sup xmlns:xlink="http://www.w3.org/1999/xlink">5</sup>
###xml 155 157 151 153 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1A</xref>
###xml 162 164 158 160 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1B</xref>
###xml 193 196 189 192 <italic xmlns:xlink="http://www.w3.org/1999/xlink">i.p</italic>
###xml 300 302 296 298 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1A</xref>
###xml 552 554 548 550 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1B</xref>
The neutrophil cell numbers in BAL fluid increased at 4 and 24 h after i.t. LPS (1.05 +/- 0.06 x 105/ml and 9.10 +/- 0.43 x 105/ml, respectively) (Figures 1A and 1B). RGDS (1, 2.5, or 5 mg/kg, i.p., 1 h before LPS) inhibited these neutrophil increases 4 h post-LPS in a dose-dependent manner (Figure 1A). Peak inhibition of 79% was observed at 5 mg/kg. At 24 h post-LPS, we evaluated and compared the inhibitory effects of RGDS (5 mg/kg) on inflammatory cell migration when administered at different times, i.e., at 1 h before or 2 h after LPS (Figure 1B). Interestingly, the inhibitory effect of RGDS on LPS-induced neutrophil increases 24 h post-LPS was similar when administered at these times (58 and 62% vs. LPS treated animals, respectively).
###end p 39
###begin p 40
###xml 0 137 0 137 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Effects of RGDS peptide on LPS-induced increases in neutrophil (A, B) and macrophage (C, D) numbers in bronchoalveolar lavage (BAL) fluid</bold>
###xml 179 184 179 184 <italic xmlns:xlink="http://www.w3.org/1999/xlink">i.p. </italic>
###xml 359 363 359 363 <italic xmlns:xlink="http://www.w3.org/1999/xlink">i.p.</italic>
###xml 545 546 543 544 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 156 160 <span type="species:ncbi:10090">mice</span>
###xml 306 310 <span type="species:ncbi:10090">Mice</span>
###xml 464 468 <span type="species:ncbi:10090">mice</span>
Effects of RGDS peptide on LPS-induced increases in neutrophil (A, B) and macrophage (C, D) numbers in bronchoalveolar lavage (BAL) fluid. Where indicated, mice were administered i.p. RGDS (1, 2.5 or 5 mg/kg) or RGES (5 mg/kg, a negative control) once 1 h before LPS treatment and sacrificed 4 h post-LPS. Mice were also administered these peptides (5 mg/kg, i.p.) once 1 h before or 2 h after LPS and sacrificed 24 h post-LPS. Values represent means +/- SEM of 5 mice per group. *Significantly different from saline treated controls, p < 0.05; +significantly different from animals treated with LPS only, p < 0.05.
###end p 40
###begin p 41
###xml 71 73 71 73 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1C</xref>
###xml 140 141 138 139 <sup xmlns:xlink="http://www.w3.org/1999/xlink">5</sup>
###xml 154 156 152 154 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1D</xref>
###xml 403 405 401 403 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p </italic>
###xml 421 423 419 421 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1D</xref>
###xml 562 566 <span type="species:ncbi:10090">mice</span>
Macrophage numbers in BAL fluid were unchanged at 4 h post-LPS (Figure 1C), but were increased 2.5-fold at 24 h post-LPS (1.04 +/- 0.08 x 105/ml) (Figure 1D), and RGDS treatment 1 h before or 2 h after LPS significantly inhibited this increase. Moreover, the inhibitory effects of RGDS were not significantly different (89 and 88% when administered at these times vs. LPS treated animals, respectively, p < 0.05) (Figure 1D). LPS+RGES (a negative control) or saline+RGDS did not affect neutrophil and macrophage cell numbers compared with LPS- or saline-treated mice, respectively.
###end p 41
###begin p 42
###xml 269 270 269 270 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2</xref>
Histological lung sections obtained 24 h post-LPS confirmed BAL findings. H&E sections of lungs fixed with paraformaldehyde revealed similar reductions in peribroncheal and intraalveolar infiltration of neutrophils in lungs treated with RGDS at different times (Figure 2).
###end p 42
###begin p 43
###xml 0 50 0 50 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Reduction in LPS-induced lung inflammation by RGDS</bold>
###xml 90 94 90 94 <italic xmlns:xlink="http://www.w3.org/1999/xlink">i.p.</italic>
###xml 52 56 <span type="species:ncbi:10090">Mice</span>
###xml 252 256 <span type="species:ncbi:10090">mice</span>
Reduction in LPS-induced lung inflammation by RGDS. Mice were administered RGDS (5 mg/kg, i.p.) once 1 h before or 2 h after LPS and were sacrificed 24 h post-LPS. Lung sections were H&E stained, as described in Methods. Representative staining from 5 mice per group are shown.
###end p 43
###begin title 44
Effect of RGDS on protein levels in BAL fluid
###end title 44
###begin p 45
###xml 174 176 174 176 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3A</xref>
###xml 181 183 181 183 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3B</xref>
###xml 308 310 308 310 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p </italic>
###xml 326 328 326 328 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3A</xref>
###xml 507 509 507 509 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p </italic>
###xml 525 527 525 527 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3B</xref>
###xml 629 633 <span type="species:ncbi:10090">mice</span>
LPS treatment significantly increased protein content in BAL fluid at 4 and 24 h post-LPS, by 1.5- and 2.6-fold, respectively, compared with saline treated controls (Figures 3A and 3B). RGDS (2.5 or 5 mg/kg, 1 h before LPS) significantly decreased protein levels at 4 h post-LPS by 70 and 73%, respectively (p < 0.05) (Figure 3A). At 24 h post-LPS, RGDS treatment 1 h before or 2 h after LPS, similarly and significantly inhibited this LPS-induced BAL protein increase by 62, and 64% vs. LPS, respectively (p < 0.05) (Figure 3B). LPS+RGES or saline+RGDS had no effect on protein accumulation compared with LPS- or saline-treated mice, respectively.
###end p 45
###begin p 46
###xml 0 77 0 77 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Effects of RGDS on LPS-induced increases in total protein levels in BAL fluid</bold>
###xml 119 124 119 124 <italic xmlns:xlink="http://www.w3.org/1999/xlink">i.p. </italic>
###xml 273 277 273 277 <italic xmlns:xlink="http://www.w3.org/1999/xlink">i.p.</italic>
###xml 468 469 466 467 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 96 100 <span type="species:ncbi:10090">mice</span>
###xml 220 224 <span type="species:ncbi:10090">Mice</span>
###xml 387 391 <span type="species:ncbi:10090">mice</span>
Effects of RGDS on LPS-induced increases in total protein levels in BAL fluid. Where indicated, mice were administered i.p. RGDS (1, 2.5 or 5 mg/kg) or RGES (5 mg/kg) once 1 h before LPS and sacrificed 4 h post-LPS (A). Mice were also administered these peptides (5 mg/kg, i.p.) once 1 h before or 2 h after LPS and were sacrificed 24 h post-LPS (B). Values represent means +/- SEM of 5 mice per group. *Significantly different from saline treated controls, p < 0.05; +significantly different from animals treated with LPS only, p < 0.05.
###end p 46
###begin title 47
Effects of RGDS on TNF-alpha and MIP-2 levels, and MMP-9 activity
###end title 47
###begin p 48
###xml 259 261 251 253 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B21">21</xref>
###xml 262 264 254 256 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B26">26</xref>
###xml 375 377 367 369 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F4">4A</xref>
###xml 382 384 374 376 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F4">4B</xref>
###xml 978 980 954 956 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F4">4D</xref>
TNF-alpha, MIP-2, and MMP-9 are representative proinflammatory mediators, which play major roles in neutrophil influx and lung damage. TNF-alpha production and MMP-9 expression require integrin signaling, as demonstrated by in vitro inflammatory cell models [21-26]. Here, we evaluated the effects of RGDS on these proinflammatory mediators in BAL fluid. As shown in Figures 4A and 4B, RGDS administered 1 h before LPS inhibited LPS-induced increases in TNF-alpha and MIP-2 levels in BAL fluid at 4 h post-LPS. Moreover, these inhibitions were in dose-dependent and peaked at 5 mg/kg when these inhibitions of TNF-alpha and MIP-2 levels were 47 and 60%, respectively. At 24 h post-LPS, LPS-induced TNF-alpha levels in BAL fluid were decreased by a fifth of those at 4 h post-LPS and MIP-2 levels were decreased to saline control (data not shown). Pre- or posttreatment with RGDS (5 mg/kg) significantly inhibited LPS-induced TNF-alpha levels by 78 and 53%, respectively (Figure 4D).
###end p 48
###begin p 49
###xml 0 85 0 81 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Effects of RGDS on LPS-induced TNF-&#945; and MIP-2 productions, and on MMP-9 activity</bold>
###xml 127 132 123 128 <italic xmlns:xlink="http://www.w3.org/1999/xlink">i.p. </italic>
###xml 287 291 283 287 <italic xmlns:xlink="http://www.w3.org/1999/xlink">i.p.</italic>
###xml 854 855 844 845 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 104 108 <span type="species:ncbi:10090">mice</span>
###xml 234 238 <span type="species:ncbi:10090">Mice</span>
###xml 773 777 <span type="species:ncbi:10090">mice</span>
Effects of RGDS on LPS-induced TNF-alpha and MIP-2 productions, and on MMP-9 activity. Where indicated, mice were administered i.p. RGDS (1, 2.5 or 5 mg/kg) or RGES (5 mg/kg) once 1 h before LPS treatment and sacrificed 4 h post-LPS. Mice were also administered these peptides (5 mg/kg, i.p.) once 1 h before or 2 h after LPS and were sacrificed 24 h post-LPS (B). TNF-alpha and MIP-2 levels in BAL fluid samples were quantified using enzyme-linked immunosorbent assays (A, B, D). Gelatinolytic activity in BAL fluid samples (C, E). Samples were analyzed by zymography followed by scanning densitometry. The 92-kD genolytic bands corresponded to MMP-9. Densities are expressed as percentages versus saline treated controls. Values represent means +/- SEM of results from 5 mice per group. *Significantly different from saline treated controls, p < 0.05; +significantly different from animals treated with LPS only, p < 0.05.
###end p 49
###begin p 50
###xml 335 337 335 337 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p </italic>
###xml 353 355 353 355 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F4">4C</xref>
###xml 502 504 502 504 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F4">4E</xref>
BAL fluid was also analyzed for evidence of MMP-9 activity by gelatin zymography. MMP-9 activity increased 7.7- and 8.0-fold vs saline treated controls at 4 and 24 h post-LPS, respectively. RGDS (2.5 or 5 mg/kg, 1 h before LPS) significantly inhibited LPS-induced MMP-9 activity in BAL fluid 4 h post-LPS (by 59 and 91%, respectively (p < 0.05) (Figure 4C). Pre- or posttreatment with RGDS (5 mg/kg) significantly inhibited LPS-induced MMP-9 activity by 83 and 70%, respectively, 24 h post-LPS (Figure 4E).
###end p 50
###begin p 51
TNF-alpha and MIP-2 levels and MMP-9 activity were similar in samples obtained from LPS and LPS-RGES treated animals at 4 or 24 h post-LPS.
###end p 51
###begin title 52
Effects of RGDS on the activation of integrin signaling and MAP kinases
###end title 52
###begin p 53
###xml 160 161 156 157 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B9">9</xref>
###xml 518 520 514 516 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F5">5A</xref>
###xml 662 664 658 660 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F5">5B</xref>
###xml 846 847 838 839 <sub xmlns:xlink="http://www.w3.org/1999/xlink">v</sub>
###xml 851 853 840 842 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3 </sub>
###xml 854 856 843 845 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B27">27</xref>
###xml 1134 1136 1123 1125 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F5">5C</xref>
###xml 1141 1143 1130 1132 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F5">5D</xref>
###xml 902 906 <span type="species:ncbi:10090">mice</span>
In vitro inhibition of integrin signaling by RGD peptide has been reported to decrease LPS-induced MAP kinase activity and TNF-alpha production in macrophages [9]. To investigate the functional link between integrin signaling and LPS-induced MAP kinase activation during the development of acute lung injury, we evaluated the inhibitory effect of RGDS on LPS-induced FAK phosphorylation in lung tissue. RGDS treatment 1 h before LPS completely inhibited LPS-induced this kinase phosphorylation at 4 h post-LPS (Figure 5A). At 24 h post-LPS, pre- or posttreatment with RGDS also completely inhibited LPS-induced FAK phosphorylation with similar potencies (Figure 5B). We also examined the fibrinogen binding activity of alveolar macrophages, because fibrinogen is a specific and physiologic ligand for activated integrin complexes, including alphavbeta3 [27]. As was expected, alveolar macrophages from mice treated with LPS were found to have increased fibrinogen binding activity in many confocal microscope fields, and RGDS treatment 1 h before or 2 h after LPS suppressed this activity at 4 or 24 h post-LPS, respectively (Figures 5C and 5D). These findings indicate that RGDS inhibits LPS-induced integrin signaling during the development of lung injury.
###end p 53
###begin p 54
###xml 0 124 0 124 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Effects of RGDS on FAK phosphorylation in lung tissue (A, B), and fibrinogen binding activity in alveolar macrophages (C, D)</bold>
###xml 189 193 189 193 <italic xmlns:xlink="http://www.w3.org/1999/xlink">i.p.</italic>
###xml 305 309 305 309 <italic xmlns:xlink="http://www.w3.org/1999/xlink">i.p.</italic>
###xml 677 678 675 676 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 143 147 <span type="species:ncbi:10090">mice</span>
###xml 254 258 <span type="species:ncbi:10090">Mice</span>
###xml 596 600 <span type="species:ncbi:10090">mice</span>
###xml 1016 1020 <span type="species:ncbi:10090">mice</span>
Effects of RGDS on FAK phosphorylation in lung tissue (A, B), and fibrinogen binding activity in alveolar macrophages (C, D). Where indicated, mice were administered RGDS or RGES (5 mg/kg, i.p.) once 1 h before LPS treatment and sacrificed 4 h post-LPS. Mice were also administered this peptide (5 mg/kg, i.p.) once 1 h before or 2 h after LPS and sacrificed 24 h post-LPS. (A, B) Western blotting with each anti-specific (phospho) FAK Ab was performed on lung tissue homogenates. Relative values for phosphorylated FAK versus FAK are indicated below the gel. Values represent means +/- SEM of 5 mice per group. *Significantly different from saline treated controls, p < 0.05; +significantly different from animals treated with LPS only, p < 0.05. (C, D) Alveolar macrophages were incubated with fibrinogen conjugated to Alexafluor-488 for 20 min. After exposure to fibrinogen for 20 min, cells were fixed and then analyzed by confocal fluorescence microscopy. The results are representative results obtained from 5 mice per group.
###end p 54
###begin p 55
###xml 7 8 7 8 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F6">6</xref>
###xml 155 157 155 157 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B28">28</xref>
###xml 158 160 158 160 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B29">29</xref>
###xml 279 281 279 281 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F6">6A</xref>
###xml 286 288 286 288 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F6">6B</xref>
###xml 326 328 326 328 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F6">6C</xref>
###xml 333 335 333 335 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F6">6D</xref>
###xml 475 477 475 477 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F6">6E</xref>
###xml 482 484 482 484 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F6">6F</xref>
Figure 6 presents LPS-induced MAP kinase phosphorylation data in lung tissue at 4 or 24 h post-LPS, which concurs with the findings of our previous study [28,29]. Phosphorylation of ERK and JNK substantially were increased 4 h post-LPS, and were either maintained (ERK) (Figures 6A and 6B) or further increased (JNK) (Figures 6C and 6D). p38 MAP kinase phosphorylation substantially increased at 4 h and this phosphorylation level was slightly reduced 24 h post-LPS (Figures 6E and 6F). RGDS treatment 1 h before LPS significantly suppressed LPS-induced phosphorylation of ERK, JNK and p38 MAP kinase 4 h post-LPS. Pre- or posttreatment with RGDS also inhibited all three MAP kinase phosphorylation 24 h post-LPS. The smallest decrease was observed for p38 MAP kinase. These findings suggest that RGD motif-dependent integrin signaling, involving FAK activation, is solidly linked to LPS-induced ERK and JNK activations during the progression of acute lung injury, and that it is weakly linked to p38 MAP kinase activation.
###end p 55
###begin p 56
###xml 0 106 0 106 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Effects of RGDS on phosphorylation of ERK1/2 (A, B), JNK1/2(C, D) and p38 MAP kinase (E, F) in lung tissue</bold>
###xml 171 175 171 175 <italic xmlns:xlink="http://www.w3.org/1999/xlink">i.p.</italic>
###xml 289 293 289 293 <italic xmlns:xlink="http://www.w3.org/1999/xlink">i.p.</italic>
###xml 679 680 677 678 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 125 129 <span type="species:ncbi:10090">mice</span>
###xml 236 240 <span type="species:ncbi:10090">Mice</span>
###xml 598 602 <span type="species:ncbi:10090">mice</span>
Effects of RGDS on phosphorylation of ERK1/2 (A, B), JNK1/2(C, D) and p38 MAP kinase (E, F) in lung tissue. Where indicated, mice were administered RGDS or RGES (5 mg/kg, i.p.) once 1 h before LPS treatment and sacrificed 4 h post-LPS. Mice were also administered these peptides (5 mg/kg, i.p.) once 1 h before or 2 h after LPS and sacrificed 24 h post-LPS. Western blotting was performed with each anti-specific (phospho) Ab on lung tissue homogenates. Relative values for phosphorylated MAP kinase versus MAP kinase, respectively, are indicated below the gel. Values represent means +/- SEM of 5 mice per group. *Significantly different from saline treated controls, p < 0.05; +significantly different from animals treated with LPS only, p < 0.05.
###end p 56
###begin title 57
###xml 29 30 25 26 <sub xmlns:xlink="http://www.w3.org/1999/xlink">v</sub>
###xml 34 36 27 29 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3 </sub>
Involvement of integrin alphavbeta3 in the inflammatory responses
###end title 57
###begin p 58
###xml 256 257 252 253 <sub xmlns:xlink="http://www.w3.org/1999/xlink">v</sub>
###xml 261 263 254 256 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3 </sub>
###xml 381 383 374 376 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B30">30</xref>
###xml 384 386 377 379 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B31">31</xref>
###xml 449 450 438 439 <sub xmlns:xlink="http://www.w3.org/1999/xlink">v</sub>
###xml 454 456 440 442 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3 </sub>
###xml 615 616 597 598 <sub xmlns:xlink="http://www.w3.org/1999/xlink">v</sub>
###xml 620 622 599 601 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3 </sub>
###xml 718 720 693 695 <sub xmlns:xlink="http://www.w3.org/1999/xlink">v </sub>
###xml 732 734 704 706 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3 </sub>
###xml 749 750 717 718 <sub xmlns:xlink="http://www.w3.org/1999/xlink">v</sub>
###xml 762 764 727 729 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3 </sub>
###xml 774 777 739 742 <italic xmlns:xlink="http://www.w3.org/1999/xlink">i.p</italic>
###xml 896 898 861 863 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p </italic>
###xml 928 930 893 895 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F7">7A</xref>
###xml 972 974 933 935 <sub xmlns:xlink="http://www.w3.org/1999/xlink">v </sub>
###xml 986 988 944 946 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3 </sub>
###xml 1080 1082 1038 1040 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p </italic>
###xml 1098 1100 1056 1058 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F7">7A</xref>
###xml 1157 1159 1115 1117 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p </italic>
###xml 1175 1177 1133 1135 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F7">7B</xref>
###xml 202 207 <span type="species:ncbi:10090">mouse</span>
The findings of the present study suggest the involvements of RGD motif-dependent integrin binding and integrin signal activation during the initiation and progression of LPS-induced lung injury in our mouse model. The RGD motif binds specifically to alphavbeta3 integrins expressed on the surface of macrophages, neutrophils, endothelial cells, and migrating smooth muscle cells [30,31]. However, no data is available on the roles of integrin alphavbeta3 in leukocyte migration to the lungs or in other pulmonary inflammatory responses. Therefore, we evaluated the involvement of RGD motif-dependent integrin alphavbeta3 binding in the key pulmonary inflammatory responses to LPS treatment using a blocking anti-alphav or anti-beta3 mAb. Anti-alphavor anti-beta3 (5 mg/kg, i.p., 1 h before LPS) significantly inhibited the neutrophil number increases in BAL fluid by 50 and 61% at 4 h post-LPS (p < 0.05), respectively (Figure 7A). Similarly, at 24 h post-LPS, anti-alphav or anti-beta3 at 2 h after LPS significantly inhibited neutrophil increases (by 44 and 50%, respectively, p < 0.05) (Figure 7A) and macrophage increases (by 71 and 60%, respectively, p < 0.05) (Figure 7B).
###end p 58
###begin p 59
###xml 21 23 17 19 <sub xmlns:xlink="http://www.w3.org/1999/xlink">v </sub>
###xml 35 37 28 30 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3 </sub>
###xml 0 132 0 125 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Effects of anti-&#945;<sub>v </sub>or anti-&#946;<sub>3 </sub>mAb on LPS-induced increases in inflammatory cell numbers and total protein levels in BAL fluid</bold>
###xml 184 185 173 174 <sub xmlns:xlink="http://www.w3.org/1999/xlink">v</sub>
###xml 196 197 182 183 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 216 220 202 206 <italic xmlns:xlink="http://www.w3.org/1999/xlink">i.p.</italic>
###xml 330 334 316 320 <italic xmlns:xlink="http://www.w3.org/1999/xlink">i.p.</italic>
###xml 619 620 603 604 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 632 645 616 617 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8225;</sup>
###xml 151 155 <span type="species:ncbi:10090">mice</span>
###xml 281 285 <span type="species:ncbi:10090">Mice</span>
###xml 506 510 <span type="species:ncbi:10090">mice</span>
Effects of anti-alphav or anti-beta3 mAb on LPS-induced increases in inflammatory cell numbers and total protein levels in BAL fluid. Where indicated, mice were administered anti-alphav, anti-beta3, or IgG (5 mg/kg, i.p.) once 1 h before LPS treatment and sacrificed 4 h post-LPS. Mice were also administered these mAbs (5 mg/kg, i.p.) once 2 h after LPS and sacrificed 24 h post-LPS. Neutrophil (A) and macrophage (B) numbers and total protein levels (C) in BAL fluid. Values represent means +/- SEM of 5 mice per group. *Significantly different from saline treated controls, p < 0.05; significantly different at 4 h (+) and 24 h (double dagger) post-LPS from animals treated with LPS only, p < 0.05.
###end p 59
###begin p 60
###xml 20 22 16 18 <sub xmlns:xlink="http://www.w3.org/1999/xlink">v </sub>
###xml 169 171 165 167 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F7">7C</xref>
###xml 223 225 216 218 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3 </sub>
Moreover, anti-alphav (1 h before or 2 h after LPS) significantly inhibited LPS-induced BAL protein increases at 4 and 24 h post-LPS by 53 and 80%, respectively (Figure 7C). Interestingly, the inhibitory effect of anti-beta3 mAb was effective only at 4 h post-LPS (59% inhibition), but it was not effective at 24 h post-LPS (7% inhibition).
###end p 60
###begin p 61
###xml 104 106 96 98 <sub xmlns:xlink="http://www.w3.org/1999/xlink">v </sub>
###xml 148 150 137 139 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3 </sub>
###xml 218 220 207 209 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p </italic>
###xml 236 242 225 231 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F8">8A, 8B</xref>
###xml 332 334 313 315 <sub xmlns:xlink="http://www.w3.org/1999/xlink">v </sub>
###xml 346 348 324 326 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3 </sub>
###xml 394 396 372 374 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F8">8D</xref>
###xml 409 411 383 385 <sub xmlns:xlink="http://www.w3.org/1999/xlink">v </sub>
###xml 423 425 394 396 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3 </sub>
###xml 560 562 531 533 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F8">8C</xref>
###xml 567 569 538 540 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F8">8E</xref>
LPS-induced increases in TNF-alpha and MIP-2 levels in BAL fluid 4 h post-LPS were reduced by anti-alphav (by 42 and 39%, respectively) or anti-beta3 mAb (by 48 and 60%, respectively) when administered 1 h before LPS (p < 0.05) (Figure 8A, 8B). At 24 h post-LPS, TNF-alpha levels were also inhibited by posttreatment with anti-alphav or anti-beta3 (45 and 38% inhibition, respectively) (Figure 8D). Anti-alphav or anti-beta3 inhibited LPS-induced MMP-9 activity in BAL fluid at 4 h post-LPS by 87 and 82% and at 24 post-LPS by 73 and 79%, respectively (Figure 8C and 8E).
###end p 61
###begin p 62
###xml 21 23 17 19 <sub xmlns:xlink="http://www.w3.org/1999/xlink">v </sub>
###xml 35 37 28 30 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3 </sub>
###xml 0 110 0 99 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Effects of anti-&#945;<sub>v </sub>or anti-&#946;<sub>3 </sub>mAb on LPS-induced TNF-&#945; and MIP-2 productions, and on MMP-9 activity</bold>
###xml 162 163 147 148 <sub xmlns:xlink="http://www.w3.org/1999/xlink">v</sub>
###xml 174 175 156 157 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 194 198 176 180 <italic xmlns:xlink="http://www.w3.org/1999/xlink">i.p.</italic>
###xml 308 312 290 294 <italic xmlns:xlink="http://www.w3.org/1999/xlink">i.p.</italic>
###xml 561 562 537 538 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 129 133 <span type="species:ncbi:10090">mice</span>
###xml 259 263 <span type="species:ncbi:10090">Mice</span>
###xml 481 485 <span type="species:ncbi:10090">mice</span>
Effects of anti-alphav or anti-beta3 mAb on LPS-induced TNF-alpha and MIP-2 productions, and on MMP-9 activity. Where indicated, mice were administered anti-alphav, anti-beta3, or IgG (5 mg/kg, i.p.) once 1 h before LPS treatment and sacrificed 4 h post-LPS. Mice were also administered these mAbs (5 mg/kg, i.p.) once 2 h after LPS and sacrificed 24 h post-LPS. TNF-alpha(A, D) andMIP-2 (B) productions, and MMP-9 activity (C, E) in BAL fluid. Values represent means +/- SEM of 5 mice per group. *Significantly different from saline treated controls, p < 0.05;+significantly different from animals treated with LPS only, p < 0.05.
###end p 62
###begin title 63
Discussion
###end title 63
###begin p 64
###xml 309 311 305 307 <sub xmlns:xlink="http://www.w3.org/1999/xlink">v </sub>
###xml 468 470 461 463 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3 </sub>
In the present study, we determined: (1) RGDS effectively inhibited LPS-induced inflammatory cell migration into the lung, protein accumulation and proinflammatory mediator production in BAL fluid; (2) RGDS inhibited LPS-induced activations of integrin signaling and MAP kinases in lung tissue; (3) anti-alphav mAb inhibited LPS-induced inflammatory cell migration into the lung, protein accumulation and proinflammatory mediator production in BAL fluid; (4) anti-beta3 was also effective at inhibiting LPS-induced inflammatory responses, except protein leakage.
###end p 64
###begin p 65
###xml 123 125 123 125 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B32">32</xref>
###xml 274 276 274 276 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B33">33</xref>
###xml 296 297 296 297 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B8">8</xref>
###xml 528 533 528 533 <italic xmlns:xlink="http://www.w3.org/1999/xlink">i.t. </italic>
###xml 911 913 907 909 <sub xmlns:xlink="http://www.w3.org/1999/xlink">v </sub>
###xml 925 927 918 920 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3 </sub>
###xml 957 958 946 947 <sub xmlns:xlink="http://www.w3.org/1999/xlink">v</sub>
###xml 962 964 948 950 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3 </sub>
###xml 1174 1175 1156 1157 <sub xmlns:xlink="http://www.w3.org/1999/xlink">v</sub>
###xml 1179 1180 1158 1159 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 1269 1270 1244 1245 <sub xmlns:xlink="http://www.w3.org/1999/xlink">v</sub>
###xml 1274 1276 1246 1248 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3 </sub>
###xml 1447 1448 1415 1416 <sub xmlns:xlink="http://www.w3.org/1999/xlink">v</sub>
###xml 1452 1453 1417 1418 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 1572 1573 1534 1535 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 1625 1627 1584 1586 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2 </sub>
###xml 1638 1640 1597 1599 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B23">23</xref>
Small-molecule RGD peptides have been known to provide specificity as well as high affinity for RGD recognizing integrins [32]. Previously, RGD-containing synthetic peptides have been shown to inhibit leukocyte recruitment and inflammatory mediator production in arthritis [33] and liver injury [8]. However, the effect of synthetic RGDS peptide on the pulmonary inflammatory responses is not evaluated. In the present study, we demonstrate that synthetic RGDS peptide can be used to inhibit pulmonary inflammatory responses to i.t. LPS. Pre- or posttreatment with RGDS significantly inhibited neutrophil and alveolar macrophage numbers in BAL fluid at 4 or 24 h post-LPS. In addition, the lung histologic findings clearly demonstrated that RGDS effectively reduced LPS-induced lung parenchymal infiltration of neutrophils with similar potency when it was administered before or after LPS. Like RGDS, anti-alphav or anti-beta3 mAb blocking of integrin alphavbeta3 ligation markedly inhibited LPS-induced increases in neutrophil and alveolar macrophage numbers in BAL fluid at 4 or 24 h post-LPS. To the best of our knowledge, this provides first evidence that integrin alphavbeta3is utilized for migration to regions of lung inflammation by both cell types. Since alphavbeta3 is one of major integrin receptors binding to the RGD motifs of extracellular matrix (ECM) proteins, these findings suggest that RGDS specifically inhibits integrin (alphavbeta3)-dependent inflammatory cell recruitment to inflamed pulmonary sites. Moreover, this inhibitory effect of RGDS is beta2integrin-independent, because it does not block beta2 integrins [23].
###end p 65
###begin p 66
###xml 241 243 237 239 <sub xmlns:xlink="http://www.w3.org/1999/xlink">v </sub>
###xml 364 366 357 359 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3 </sub>
###xml 685 687 678 680 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B34">34</xref>
###xml 720 722 709 711 <sub xmlns:xlink="http://www.w3.org/1999/xlink">v </sub>
###xml 743 744 728 729 <sub xmlns:xlink="http://www.w3.org/1999/xlink">v</sub>
###xml 748 750 730 732 <sub xmlns:xlink="http://www.w3.org/1999/xlink">5 </sub>
###xml 762 763 740 741 <sub xmlns:xlink="http://www.w3.org/1999/xlink">v</sub>
###xml 767 768 742 743 <sub xmlns:xlink="http://www.w3.org/1999/xlink">6</sub>
###xml 786 787 757 758 <sub xmlns:xlink="http://www.w3.org/1999/xlink">v</sub>
###xml 791 793 759 761 <sub xmlns:xlink="http://www.w3.org/1999/xlink">5 </sub>
###xml 939 940 903 904 <sub xmlns:xlink="http://www.w3.org/1999/xlink">v</sub>
###xml 944 946 905 907 <sub xmlns:xlink="http://www.w3.org/1999/xlink">5 </sub>
###xml 954 955 911 912 <sub xmlns:xlink="http://www.w3.org/1999/xlink">v</sub>
###xml 959 961 913 915 <sub xmlns:xlink="http://www.w3.org/1999/xlink">6 </sub>
###xml 1055 1057 1009 1011 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B35">35</xref>
###xml 1058 1060 1012 1014 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B37">37</xref>
###xml 1135 1137 1086 1088 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3 </sub>
Another important finding made in the present study was that pre- or posttreatment with RGDS significantly inhibited LPS-induced increases in total protein in BAL fluid at 4 and 24 h post-LPS. Similarly, pre- or posttreatment with anti-alphav significantly inhibited total protein level increases in BAL fluid as potent as RGDS at both time points, while anti-beta3 was not effective at 24 h post-LPS. Although BAL protein is not a very specific way to measure pulmonary permeability, this discrepancy suggests that prevention of pulmonary edema and other inflammatory responses, such as leukocyte migration and inflammatory mediator production, are regulated by different mechanisms [34], and that blockade of the alphav integrins (e.g. alphavbeta5 and/or alphavbeta6) other than alphavbeta5 is likely to be responsible for the protective effects of RGDS on BAL protein accumulation. Indeed, a blocking antibody against the integrin alphavbeta5 or alphavbeta6 protected development of lung vascular permeability in different models of acute lung injury [35-37]. Additional studies are required to identify a physiological role of beta3 integrin in the development of pulmonary edema during acute lung injury.
###end p 66
###begin p 67
###xml 902 904 886 888 <sub xmlns:xlink="http://www.w3.org/1999/xlink">v </sub>
###xml 916 918 897 899 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3 </sub>
###xml 1218 1219 1191 1192 <sub xmlns:xlink="http://www.w3.org/1999/xlink">v</sub>
###xml 1223 1225 1193 1195 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3 </sub>
The productions of TNF-alpha and chemokines are essentially required for early LPS-mediated neutrophil recruitment and lung damage. Moreover, MMPs, like MMP-9, are required to allow activated neutrophils to transverse ECM barriers after adhesion, and to enable transendothelial cell migration. Therefore, RGDS may protect against LPS-induced acute lung injury by decreasing the productions or activities of these proinflammatory mediators. According to this concept, our data indicate RGDS significantly inhibited LPS-induced TNF-alpha and MIP-2 productions and MMP-9 activity in BAL fluid at 4 or 24 h post-LPS. Although its inhibitory effects on TNF-alpha production and MMP-9 activity were more potent in the pretreatment model compared with the posttreatment model at 24 h post-LPS, the inhibition was evident when it was administered 2 h after LPS. Similarly, pre- or posttreatment with anti-alphav or anti-beta3 also blocked LPS-induced TNF-alpha or MIP-2 levels and MMP-9 activity in BAL fluid at 4 or 24 h post-LPS as potently as RGDS. Our results suggest that the inhibitory effect of RGDS on LPS-induced these inflammatory mediator productions or activity during the development of acute lung injury is alphavbeta3 integrin-dependent.
###end p 67
###begin p 68
###xml 150 152 146 148 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B38">38</xref>
###xml 153 155 149 151 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B41">41</xref>
###xml 256 257 248 249 <sub xmlns:xlink="http://www.w3.org/1999/xlink">v</sub>
###xml 261 263 250 252 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3 </sub>
###xml 346 348 331 333 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B13">13</xref>
###xml 691 692 672 673 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B9">9</xref>
###xml 1144 1146 1125 1127 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B28">28</xref>
###xml 1147 1149 1128 1130 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B29">29</xref>
###xml 1573 1575 1554 1556 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B42">42</xref>
###xml 1765 1766 1734 1735 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B9">9</xref>
###xml 1922 1924 1891 1893 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B28">28</xref>
###xml 1925 1927 1894 1896 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B29">29</xref>
These proinflammatory mediators are known to be regulated at the transcriptional level by MAP kinase pathways and nuclear factor kappa B (NF-kappaB) [38-41]. Previously, we demonstrated that the RGD motifs of ECM entities that associate with integrin alphavbeta3 signaling appears to be involved in NF-kappaB activation during acute lung injury [13]. In the present study, we report that integrin signaling-dependent MAP kinase activations are associated with LPS-induced acute lung injury. The regulation of multiple cellular events in the context of in vivo LPS stimulation is complex. Because of the extreme bioactivity of many molecules (i.e., TNF-alpha) produced by inflammatory cells [9], these may affect optimal LPS signaling to MAP kinase activation correlating with kinetics at many levels. Previously, we demonstrated the kinetics of LPS-induced phosphorylation of these kinases in lung tissue. MAP kinase phosphorylation beginning 2 h after LPS, substantially increased at 4 h and progressively further increased (JNK activation), were maintained (ERK activation), or decreased (p38 MAP kinase activation) for up to 24 h after LPS [28,29], which concurs with the kinetic results of our present study. Pre- or posttreatment with RGDS markedly inhibited LPS-induced phosphorylation of these MAP kinases in lung tissues at 4 or 24 h post-LPS, although it was less effective at inhibiting p38 MAP kinase phosphorylation 24 h post-LPS. In-line with our in vivo data, LPS signaling activated the integrin signal that amplifies ERK and JNK activations in macrophages [42]. Moreover, inhibition of LPS-induced cell adhesion and integrin signaling by RGD resulted in reductions in these MAP kinase activities in the order ERK approximately JNK > p38 MAP kinase [9]. Previously, we found that inhibition of each of these MAP kinases reduced the LPS-induced proinflammatory mediator productions during acute lung injury [28,29]. Furthermore, inhibition of these kinases, except ERK, reduced LPS-induced phosphorylation and degradation of IkappaB-alpha and NF-kappaB activation. Collectively, these findings suggest that the specific inhibition of integrin signaling by RGDS results in suppression of proinflammatory mediator productions through the MAP-kinase leading to NF-kappaB pathway or each different pathway.
###end p 68
###begin p 69
###xml 122 124 122 124 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B43">43</xref>
###xml 125 127 125 127 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B45">45</xref>
###xml 190 192 190 192 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B46">46</xref>
###xml 289 290 285 286 <sub xmlns:xlink="http://www.w3.org/1999/xlink">v</sub>
###xml 294 295 287 288 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 491 493 480 482 <sub xmlns:xlink="http://www.w3.org/1999/xlink">v </sub>
###xml 505 507 491 493 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3 </sub>
###xml 584 586 570 572 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B13">13</xref>
###xml 668 670 654 656 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B47">47</xref>
###xml 671 673 657 659 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B49">49</xref>
Integrin-mediated adhesion and/or clustering led to enhance the tyrosine phosphorylation of Src tyrosine kinases and FAK [43-45], and this pathway activates the classic Ras-MEK-ERK cascade [46]. We do suggest the involvement of a pathway initiated by FAK activation through integrin (alphavbeta3) signaling during LPS-induced acute lung injury, because RGDS suppressed LPS-induced FAK phosphorylation in lung tissue and fibrinogen binding activity in alveolar macrophages. Indeed, anti-alphav or anti-beta3 mAb inhibited LPS-induced c-Src and FAK activation during acute lung injury [13]. Integrin-FAK-ERK/-JNK pathways have been documented in other in vitro systems [47-49].
###end p 69
###begin title 70
Conclusion
###end title 70
###begin p 71
###xml 61 62 57 58 <sub xmlns:xlink="http://www.w3.org/1999/xlink">v</sub>
###xml 66 67 59 60 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 263 264 252 253 <sub xmlns:xlink="http://www.w3.org/1999/xlink">v</sub>
###xml 288 289 274 275 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 622 623 604 605 <sub xmlns:xlink="http://www.w3.org/1999/xlink">v</sub>
###xml 641 649 623 631 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vivo </italic>
###xml 702 703 684 685 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B8">8</xref>
###xml 704 706 686 688 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B32">32</xref>
###xml 707 709 689 691 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B50">50</xref>
The present study suggests that RGDS inhibits integrin (alphavbeta3)-dependent induction of inflammatory cell migration into the lungs, and proinflammatory mediator production. Our data also suggest that the protective effect of RGDS on pulmonary leakage is alphav-dependent, but not beta3. Importantly, posttreatment with RGDS was also highly effective at reducing these inflammatory responses correlated with its inhibitory effect on integrin signaled MAP kinase pathways. In addition, blockading the integrin-FAK-MAP kinase pathway with RGDS may reduce lung injury progression. Since RGDS has high specificity for alphavintegrins and the in vivo efficacy to access target cells as a small-molecule [8,32,50], it may effectively attenuate inflammatory cascade during LPS-induced development of acute lung injury.
###end p 71
###begin title 72
Abbreviations
###end title 72
###begin p 73
RGDS: Arg-Gly-Asp-Ser; RGES: Arg-Gly-Glu-Ser; LPS: lipopolysaccharide; MAP: mitogen-activated protein; BAL: bronchoalveolar lavage; TNF-alpha: tumor necrosis factor-alpha; FAK: focal adhesion kinase; MIP: macrophage inflammatory protein; MMP-9: matrix metalloproteinase; ECM: extracellular matrix; NF-kappaB: nuclear factor kappa B.
###end p 73
###begin title 74
Competing interests
###end title 74
###begin p 75
The authors declare that they have no competing interests.
###end p 75
###begin title 76
Authors' contributions
###end title 76
###begin p 77
CM, JRH, HJP, and JH carried animal studies. CM performed the statistical analysis. JLK conceived of the study, participated in its design and coordination, and drafted and edited the manuscript. All authors read and approved the final manuscript.
###end p 77
###begin title 78
Acknowledgements
###end title 78
###begin p 79
The authors thank Dr. Min-Sun Cho for her assistance with the histological study. This work was supported by a Korea Research Foundation Grant (KRF-2006-311-E00175).
###end p 79
###begin article-title 80
The acute respiratory distress syndrome
###end article-title 80
###begin article-title 81
###xml 23 24 19 20 <sub xmlns:xlink="http://www.w3.org/1999/xlink">v</sub>
###xml 28 30 21 23 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3 </sub>
Identification of alphavbeta3 as a heterotypic ligand for CD31/PECAM-1
###end article-title 81
###begin article-title 82
In vivo modulation of host response and macrophage behavior by polymer networks grafted with fibronectin-derived biomimetic oligopeptides: the role of RGD and PHSRN domains
###end article-title 82
###begin article-title 83
Regulation of interactions between cells and extracellular matrix command performance on several stages
###end article-title 83
###begin article-title 84
Macrophage matrix metalloproteinase-2/-9 gene and protein expression following adhesion to ECM-derived multifunctional matrices via integrin complexation
###end article-title 84
###begin article-title 85
Leucocyte activation by collagen-stimulated platelets in whole blood
###end article-title 85
###begin article-title 86
Targeting of angiogenic endothelial cells at sites of inflammation by dexamethasone phosphate-containing RGD peptide liposomes inhibits experimental arthritis
###end article-title 86
###begin article-title 87
###xml 48 49 44 45 <sub xmlns:xlink="http://www.w3.org/1999/xlink">5</sub>
###xml 53 55 46 48 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1 </sub>
###xml 95 98 <span type="species:ncbi:10116">rat</span>
Cyclic RGD peptides with high affinity for alpha5beta1 integrin protect genetically fat Zucker rat livers from cold ischemia/reperfusion injury
###end article-title 87
###begin article-title 88
Interaction of matrix with integrin receptors is required for optimal LPS-induced MAP kinase activation
###end article-title 88
###begin article-title 89
Pre-B cells adhere to fibronectin via interactions of integrin alpha 5/alpha V with RGDS as well as of integrin alpha 4 with two distinct V region sequences at its different binding sites
###end article-title 89
###begin article-title 90
CD31/PECAM-1 is a ligand for alpha v beta 3 integrin involved in adhesion of leukocytes to endothelium
###end article-title 90
###begin article-title 91
###xml 41 46 <span type="species:ncbi:10090">mouse</span>
Efficacy of a technique for exposing the mouse lung to particles aspirated from the pharynx
###end article-title 91
###begin article-title 92
Src tyrosine kinases mediate activations of NF-kappaB and integrin signal during lipopolysaccharide-induced acute lung injury
###end article-title 92
###begin article-title 93
Coordinate interactions of Csk, Src, and Syk kinases with alphaIIbeta3 initiate integrin signaling to the cytoskeleton
###end article-title 93
###begin article-title 94
The beta3 integrin antagonist m7E3 reduces matrix metalloproteinase activity and smooth muscle cell migration
###end article-title 94
###begin article-title 95
###xml 9 14 <span type="species:ncbi:9606">human</span>
In vitro human tumor sensitivity assay using cell counting and sizing
###end article-title 95
###begin article-title 96
###xml 23 34 <span type="species:ncbi:10141">guinea pigs</span>
###xml 63 69 <span type="species:ncbi:3635">cotton</span>
Pulmonary responses of guinea pigs to consecutive exposures to cotton dust
###end article-title 96
###begin article-title 97
An in vitro hamster bioassay to assess the toxicity of particulates for the lung
###end article-title 97
###begin article-title 98
Determination of protein: a modification of the Lowry method that gives a linear photometric response
###end article-title 98
###begin article-title 99
Genistein prevents nuclear factor-kappa B activation and acute lung injury induced by lipopolysaccharide
###end article-title 99
###begin article-title 100
Integrins: Signaling, disease, and therapy
###end article-title 100
###begin article-title 101
###xml 74 91 <span type="species:ncbi:777">Coxiella burnetii</span>
###xml 142 147 <span type="species:ncbi:9606">human</span>
alpha(v)beta(3) integrin and bacterial lipopolysaccharide are involved in Coxiella burnetii-stimulated production of tumor necrosis factor by human monocytes
###end article-title 101
###begin article-title 102
The kringle domain of urokinase-type plasminogen activator potentiates LPS-induced neutrophil activation through interaction with {alpha}V{beta}3 integrins
###end article-title 102
###begin article-title 103
Phosphorylation-dependent interaction of osteopontin with its receptors regulates macrophage migration and activation
###end article-title 103
###begin article-title 104
###xml 41 46 <span type="species:ncbi:9606">human</span>
Aggregation of beta2 integrins activates human neutrophils through the IkappaB/NF-kappaB pathway
###end article-title 104
###begin article-title 105
Regulation of interleukin 1 signaling through integrin binding and actin reorganization: disparate effects on NF-kappaB and stress kinase pathways
###end article-title 105
###begin article-title 106
Osteopontin and beta 3 integrin are coordinately expressed in regenerating endothelium in vivo and stimulate Arg-Gly-Asp-dependent endothelial migration in vitro
###end article-title 106
###begin article-title 107
###xml 22 23 22 23 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
Inhibition of c-Jun NH2-terminal kinase or extracellular signal-regulated kinase improves lung injury
###end article-title 107
###begin article-title 108
p38 mitogen-activated protein kinase up-regulates LPS-induced NF-kappaB activation in the development of lung injury and RAW 264.7 macrophages
###end article-title 108
###begin article-title 109
The role of alphav integrins during angiogenesis
###end article-title 109
###begin article-title 110
Function and interaction of integrins
###end article-title 110
###begin article-title 111
Structural basis for ligand recognition by RGD (Arg-Gly-Asp)-dependent integrins
###end article-title 111
###begin article-title 112
###xml 53 57 <span type="species:ncbi:10116">rats</span>
Synthetic fibronectin peptides suppress arthritis in rats by interrupting leukocyte adhesion and recruitment
###end article-title 112
###begin article-title 113
###xml 106 113 <span type="species:ncbi:9986">rabbits</span>
The role of leukocyte emigration and IL-8 on the development of lipopolysaccharide-induced lung injury in rabbits
###end article-title 113
###begin article-title 114
###xml 56 57 52 53 <sub xmlns:xlink="http://www.w3.org/1999/xlink">v</sub>
###xml 61 63 54 56 <sub xmlns:xlink="http://www.w3.org/1999/xlink">6 </sub>
Ligation of protease-activated receptor a enhances alphavbeta6 integrin-dependent TGF-beta activation and promotes acute lung injury
###end article-title 114
###begin article-title 115
TGF-beta is a critical mediator of acute lung injury
###end article-title 115
###begin article-title 116
Integrin alphavbeta5 regulates lung vascular permeability and pulmonary endothelial barrier function
###end article-title 116
###begin article-title 117
###xml 70 89 <span type="species:ncbi:210">Helicobacter pylori</span>
Mitogen-activated protein kinases and nuclear factor-kappa B regulate Helicobacter pylori-mediated interleukin-8 release from macrophages
###end article-title 117
###begin article-title 118
In vivo antioxidant treatment suppresses nuclear factor-kappa B activation and neutrophilic lung inflammation
###end article-title 118
###begin article-title 119
###xml 0 28 <span type="species:ncbi:12721">Human immunodeficiency virus</span>
Human immunodeficiency virus-1-tat induces matrix metalloproteinase-9 in monocytes through protein tyrosine phosphatase-mediated activation of nuclear transcription factor NF-kappaB
###end article-title 119
###begin article-title 120
Inhibition of MAP kinase kinase prevents cytokine and prostaglandin E2 production in lipopolysaccharide-stimulated monocytes
###end article-title 120
###begin article-title 121
CD11b/CD18 acts in concert with CD14 and Toll-like reeptor (TLR) 4 to elicit full lipopolysaccharide and taxol-inducible gene expression
###end article-title 121
###begin article-title 122
c-Src enhances the spreading of src-/- fibroblasts on fibronectin by a kinase-independent mechanism
###end article-title 122
###begin article-title 123
Integrin alpha2-mediated ERK and calpain activation play a critical role in cell adhesion and motility via focal adhesion kinase signaling
###end article-title 123
###begin article-title 124
pp125FAK a structurally distinctive protein-tyrosine kinase associated with focal adhesions
###end article-title 124
###begin article-title 125
Signaling through focal adhesion kinase
###end article-title 125
###begin article-title 126
Alpha 3 beta 1 integrin promotes keratinocyte cell survival through activation of a MEK/ERK signaling pathway
###end article-title 126
###begin article-title 127
alphavbeta3 integrins and Pyk2 mediate insulin-like growth factor I activation of Src and nitrogen-activated protein kinase in 3T3-L1 cells
###end article-title 127
###begin article-title 128
JSAP1/JIP3 cooperates with focal adhesion kinase to regulate c-Jun N-terminal kinase and cell migration
###end article-title 128
###begin article-title 129
Phage'libraries displacing cyclic peptides with different ring sizes: ligand specificities of the RGD-directed integrins
###end article-title 129

